Filing Details

Accession Number:
0001209191-14-017772
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-03-06 14:46:41
Reporting Period:
2014-03-04
Filing Date:
2014-03-06
Accepted Time:
2014-03-06 14:46:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
949699 Pharmacyclics Inc PCYC Pharmaceutical Preparations (2834) 943148201
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1190985 H Eric Halvorson C/O Pharmacyclics, Inc.
995 East Arques Avenue
Sunnyvale CA 94085
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-03-04 2,500 $14.26 3,500 No 4 M Direct
Common Stock Acquisiton 2014-03-04 148 $15.02 3,648 No 4 M Direct
Common Stock Acquisiton 2014-03-04 824 $28.47 4,472 No 4 M Direct
Common Stock Disposition 2014-03-04 3,472 $138.33 1,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2014-03-04 2,500 $0.00 2,500 $14.26
Common Stock Stock Option (Right to Buy) Disposition 2014-03-04 148 $0.00 148 $15.02
Common Stock Stock Option (Right to Buy) Disposition 2014-03-04 824 $0.00 824 $28.47
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
12,500 2011-12-15 2021-12-15 No 4 M Direct
0 2012-01-03 2022-01-03 No 4 M Direct
0 2012-04-02 2022-04-02 No 4 M Direct
Footnotes
  1. Immediately exercisable option granted to Reporting Person pursuant to issuer's 2004 Equity Incentive Award Plan in a transaction exempt under Rule 16b-3(d). The shares are subject to repurchase upon optionee's termination of service prior to vesting of such shares. The repurchase right lapses in equal and succesive annual installments for the five (5) years following 12/15/2011.
  2. Represents grant of fully-vested option pursuant to Issuer's 2004 Equity Incentive Award Plan in lieu of payment of quarterly retainer and/or meeting fees earned for service on Issuer's Board of Directors